INTRODUCTION
============

Elevated LDL cholesterol (LDL-C) is a major cause of cardiovascular disease (CVD), and clinical trials have conclusively shown that LDL-C-lowering therapy reduces the risk of developing CVD \[[@B1][@B2]\]. For these reasons, the United States National Institutes of Health National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III continues to identify elevated LDL-C as the primary target of cholesterol-lowering therapy \[[@B3]\]. However, measuring LDL-C concentration alone was insufficient to identify all individuals with incident CVD since a substantial proportion of these events occur in patients with a normal LDL-C concentration \[[@B4]\]. This has led to a search for other factors that may be implicated in the pathogenesis of atherosclerosis and CVD.

Metabolic syndrome (MetS), a constellation of CVD risk factors relating to the concentration of certain lipids other than LDL-C (hypertriglyceridemia, low HDL cholesterol \[HDL-C\], and insulin resistance) and non-lipid factors (hypertension and abdominal obesity), has been proposed as a criterion that would be helpful in identifying those patients who are at high risk of CVD regardless of LDL-C level \[[@B5]\]. The ATP III report has identified MetS as a secondary target of therapy in the management of CVD, in addition to LDL-C-lowering therapy \[[@B3][@B6]\].

Small dense LDL (sdLDL), which is not a MetS criterion, is a distinct LDL subclass primarily identified through size separation using gradient gel electrophoresis \[[@B7]\]. sdLDL has gained attention because of its pathogenicity and correlation with metabolic disease. It has been shown to have a higher degree of penetration of the arterial wall, a lower binding affinity for LDL receptors, a prolonged plasma half-life, and a lower resistance to oxidative stress relative to large buoyant LDL \[[@B8][@B9]\]. Clinical studies have consistently demonstrated that the accumulation of sdLDL particles in the plasma is associated with an increased risk of CVD \[[@B10]\]. Furthermore, the measurement of sdLDL cholesterol (sdLDL-C) concentration was useful in the assessment of the presence of CVD \[[@B11][@B12]\] and its severity \[[@B13]\]. In addition, a recent publication by Arai et al. \[[@B14]\] demonstrated the utility of the sdLDL-C concentration as a predictive marker for CVD incidence.

Patients with MetS may not present with an elevated LDL-C concentration. However, a qualitative abnormality in LDL-C, such as sdLDL-C, is associated with MetS \[[@B15]\]. Nozue et al. \[[@B16]\] reported that the sdLDL-C concentration measured by using the heparin-Magnesium precipitation method was significantly higher in patients with coronary artery disease and MetS than in patients without MetS. Nakano et al. \[[@B17]\] and Sugino et al. \[[@B18]\] conducted cross-sectional studies using patients with MetS and healthy controls, and observed a higher concentration of sdLDL-C in patients with MetS. However, the component of MetS that is most closely associated with an elevated sdLDL-C concentration has not been identified.

In this study, we evaluated the association between sdLDL-C concentration or sdLDL-C/LDL-C ratio and metabolic parameters that included each component of MetS, and attempted to identify the major component of MetS contributing to an elevated sdLDL-C concentration.

METHODS
=======

1. Study participants
---------------------

Four hundred and forty-seven subjects (225 men; 222 women) with MetS were obtained from the Korean Metabolic Syndrome Research Initiatives-Seoul cohort study (2006-2010) \[[@B19]\] by using simple random sampling in subgroup with MetS. Age- and sex-matched healthy controls (181 men; 179 women) without MetS were also randomly selected from healthy subgroup of the same cohort. All subjects completed the lifestyle questionnaire and anthropometric survey, and serum samples for biochemical tests were collected in accordance with the protocols outlined by the Institutional Review Board of Severance Hospital, Yonsei University, Seoul, Korea. Serum samples were stored frozen below -80℃ until further analyses.

2. Diagnosis of MetS and definition of healthy status
-----------------------------------------------------

MetS was diagnosed according to the NCEP ATP III definition of MetS, with the exception of two components, i.e., fasting glucose (fasting blood glucose \>5.6 mmol/L) and waist circumference (waist circumference \[WC\]; \>90 cm for mem; \>85 cm for women), which had been modified for the Asian population \[[@B20]\]. Healthy population was defined as individuals without renal disease, hepatic disease, infectious diseases, or malignancy, as well as, history of familial lipid disorders or dyslipidemia-related diseases.

3. Biochemical tests
--------------------

Frozen serum samples of the study participants were thawed and used for biochemical tests. Serum glucose concentrations were measured by using the hexokinase method (Roche Diagnostics, Mannheim, Germany) with a Hitachi 7600 clinical chemistry analyzer (Hitachi Ltd., Tokyo, Japan). Total cholesterol (TC) and triglyceride (TG) concentrations were determined by using enzymatic methods (Sekisui, Tokyo, Japan and Roche Diagnostics, respectively), and HDL-C and LDL-C were determined by using a direct enzymatic procedure (Sekisui) with a Hitachi 7600 analyzer. Serum sdLDL-C concentrations were measured by using a homogeneous enzymatic assay (Denka Seiken, Tokyo, Japan) with a Hitachi-7600 analyzer. Serum insulin concentration was determined by using an automated enzyme chemiluminescence immunoassay (DxI; Beckman Coulter, Brea, CA, USA). As a surrogate index of insulin resistance, homeostasis model assessment of insulin resistance (HOMA-IR) was calculated by using the formula of Matthews et al. \[[@B21]\] as follows: fasting plasma insulin (mIU/L)×fasting plasma glucose (mmol/L)/22.5.

4. Statistical analyses
-----------------------

Participants\' characteristics were compared according to MetS status by using the Mann-Whitney\'S U tests for continuous measures and chi-square tests for categorical measures. The median values of sdLDL-C concentration were compared between subgroups classified according to whether subjects met or did not meet the criteria for each MetS component. A correlation between the sdLDL-C concentration or sdLDL-C/LDL-C ratio and age or another metabolic parameter was examined. The strength of correlation was interpreted according to the size of correlation coefficient (*r*) as strong (0.8≤ \|r\<1), moderate (0.5≤\|r\|\<0.8), or weak (0.1 ≤\|r\|\<0.5). Multiple linear regression analysis by the \"enter\" procedure was performed to identify the independent variables associated with plasma sdLDL-C concentration. To perform this analysis, the criteria for MetS (WC, TG, HDL-C, systolic blood pressure, diastolic blood pressure \[DBP\], fasting glucose), age, and LDL-C were included in the model. All statistical analyses were conducted by using the Analyse-it Method Evaluation Edition version 2.22 software (Analyse-it Software Ltd., Leeds, UK), GraphPad Prism version 6.04 (GraphPad Software, La Jolla, CA, USA), or PASW Statistics 18.0.0 tool (IBM Corp., Armonk, NY, USA). *P* values \<0.05 were considered statistically significant.

RESULTS
=======

1. Characteristics of the study groups
--------------------------------------

The characteristics of participants grouped by MetS status are summarized in [Table 1](#T1){ref-type="table"}. Subjects with MetS had a significantly higher sdLDL-C concentration and sdLDL-C/LDL-C ratio than healthy controls, in both men and women ([Fig. 1](#F1){ref-type="fig"}). In addition, subjects presenting with MetS had a higher body mass index, fasting insulin level, HOMA-IR, and non-HDL-C concentration than healthy controls in both genders ([Table 1](#T1){ref-type="table"}). TC and LDL-C concentrations were higher in women with MetS than without MetS. Reference intervals for sdLDL-C, determined by using non-parametric methods (2.5 and 97.5 percentiles) in healthy controls, were 0.30-1.86 mmol/L for men and 0.27-1.61 mmol/L for women.

Subjects presenting with MetS included a higher percentage with high LDL-C (\>4.14 mmol/L) as defined by the NCEP \[[@B3]\] than healthy men and women. However, the percentage with optimal LDL-C (\<2.6 mmol/L) was lower in individuals with MetS than without MetS for women only. The proportion of subjects with a sdLDL-C concentration \<0.5 mmol/L was significantly lower among both men and women with MetS than without MetS ([Table 1](#T1){ref-type="table"}). The proportion with sdLDL-C \>1.0 mmol/L was higher in individuals with MetS than without MetS.

2. Differences in sdLDL-C concentration or sdLDL-C/LDL-C ratio in relation to the presence or absence of each MetS component
----------------------------------------------------------------------------------------------------------------------------

[Fig. 1](#F1){ref-type="fig"} shows that patients with MetS had higher sdLDL-C concentrations than healthy controls, in both men and women. When the median values of sdLDL-C concentration were compared between subgroups, divided according to whether subjects met or did not meet the criteria for each MetS component ([Table 2](#T2){ref-type="table"}), a significant difference in the sdLDL-C concentration was only found between subgroups divided according to TG criteria. There were no differences in sdLDL-C concentration in the presence or absence of other MetS components. A similar pattern was observed for healthy controls. Subjects who met the TG criteria showed a higher sdLDL-C concentration than those who did not. In addition, sdLDL-C concentration was significantly different between healthy controls who met the WC criteria and those who did not.

The ratio of sdLDL-C/LDL-C was also significantly increased in subjects who met the TG criteria, regardless of gender or disease status ([Table 2](#T2){ref-type="table"}). However, the presence or absence of the WC component did not significantly alter this ratio. A difference in the sdLDL-C/LDL-C ratio was observed between healthy men who met the HDL-C criteria and those who did not.

3. Association of the sdLDL-C concentration with other metabolic parameters
---------------------------------------------------------------------------

Among those univariate correlations analysis in all subjects; TC, LDL-C, and TG each showed moderate correlation with sdLDL-C concentration (r=0.738, 0.508, and 0.543, respectively, for men; 0.748, 0.692, and 0.653, respectively, for women), whereas only TG showed moderate correlation with sdLDL-C/LDL-C ratio (r=0.789 for men; 0.745 for women).

When subpopulations divided according to MetS status were analyzed, in the healthy group, TC, LDL-C, and TG each showed moderate correlation with sdLDL-C concentration (r=0.665, 0.574, and 0.659 for TC, LDL-C, and TG, respectively), whereas only TG showed moderate correlation with sdLDL-C/LDL-C ratio (r=0.749). In the MetS group, the strength of the correlation between TG and sdLDL-C concentration was diminished (r=0.403), while other factors retained moderate correlation with sdLDL-C (r=0.589 for TC; 0.752 for LDL-C). However, only TG showed moderate correlation with sdLDL-C/LDL-C ratio (r=0.767).

To elucidate each factor\'s quantitative contribution to the sdLDL-C concentration and the sdLDL-C/LDL-C ratio, multiple linear regression analysis using anthropometric and metabolic parameters was conducted for the whole study population ([Table 3](#T3){ref-type="table"}). The most significant determinant of plasma sdLDL-C concentration was LDL-C, followed by TG concentration, and fasting glucose level; WC in men and age in women apparently had an additive effect on sdLDL-C concentration. For the sdLDL-C/LDL-C ratio, TG concentration was the most significant contributing factor in both genders.

LDL-C, TG, fasting glucose and WC were common significant determinants of plasma sdLDL-C in both MetS and healthy subjects ([Table 4](#T4){ref-type="table"}). However, the effect of LDL-C was no longer observed when sdLDL-C/LDL-C ratio was used as the dependent factor. The regression coefficients of TG for sdLDL-C concentration and sdLDL-C/LDL-C ratio in the healthy group (0.2706 and 9.1815, respectively) were noticeably higher than in the MetS group (0.1747 and 6.9518, respectively), consistent with the diminished strength of correlation between TG and sdLDL-C concentration in the MetS group. While the association between DBP and sdLDL-C concentration or sdLDL-C/LDL-C ratio was only significant in the MetS group, HDL-C concentration showed significant association with sdLDL-C concentration and sdLDL-C/LDL-C ratio in the healthy population only ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

In this study, we evaluated sdLDL-C concentration in both healthy subjects and patients with MetS. The study population was subdivided according to the presence or absence of each MetS component, and the concentration of sdLDL-C and the sdLDL-C/LDL-C ratio in each subgroup were compared. We found that the sdLDL-C concentration and sdLDL-C/LDL-C ratio were higher in patients with MetS who met TG component criteria compared with those who did not ([Table 2](#T2){ref-type="table"}), while the other MetS components were not associated with an elevated sdLDL-C concentration. The findings were reproducible in both genders and also in the healthy population, with an exception that additional effect of WC or HDL-C on the concentration of sdLDL-C or sdLDL-C/LDL-C ratio was found in healthy group. A possible explanation of this phenomenon is a larger effect of TG on sdLDL-C compared with that of WC or HDL-C, which would be sufficient to make a statistically significant difference even in patients with MetS whose baseline for sdLDL-C is higher than that of healthy population.

In correlation and multiple linear regression analyses, the TG concentration was a significant determinant of sdLDL-C concentration ([Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}), in line with the previous studies on the association between sdLDL-C and TG concentrations \[[@B17][@B18][@B22]\]. However, to the best of our knowledge, none of these studies analyzed differences in sdLDL-C concentration according to the presence or absence of each MetS component as done in this study. A previous cross-sectional study on the relationship between sdLDL particle number, measured by nuclear magnetic resonance, and each MetS component also showed that only TG and HDL-C concentrations were strongly correlated with sdLDL particle number \[[@B15]\].

The precise mechanism underlying the association between TG and sdLDL-C concentrations has not yet been elucidated. It has been speculated that, when the TG concentration is normal, cholesteryl ester transfer protein preferentially mediates the transfer of HDL cholesteryl esters to LDL particles \[[@B23][@B24]\]. In hypertriglyceridemia, the large very low-density lipoprotein (VLDL) particles are preferred acceptors of HDL-derived cholesteryl esters owing to their increased numbers \[[@B23][@B24]\]. Under these conditions, there are high net transfer rates of cholesteryl esters from HDL to VLDL, and of TG from VLDL to both LDL and HDL. The TG-enriched LDL particles are targets for hepatic lipase activity that hydrolyzes phospholipid and TG, leading to the formation of sdLDL particles \[[@B23][@B24]\].

TG concentration is an independent risk factor in the development of CVD \[[@B25][@B26][@B27]\]. While the number of TG-rich lipoprotein particles or level of TG-rich lipoprotein cholesterol could contribute to the development of atherosclerosis in hypertriglyceridemia, alterations in other lipoprotein phenotypes induced by hypertriglyceridemia could also be important factors in this process \[[@B28]\]. An increased number of remnant-like lipoproteins and sdLDL particles were simultaneously present in fasting hypertriglyceridemia or postprandial lipidemia, and in both cases, highly atherogenic \[[@B28]\]. In the present study, the TG concentration showed relatively strong correlation with sdLDL-C concentration, and is considered a significant determinant of sdLDL-C concentration ([Table 3](#T3){ref-type="table"}). And the association between sLDL-C/LDL-C ratio, which may rise due to increased sdLDL without an increase of LDL, and TG was even stronger than that between sdLDL-C concentration and TG ([Table 4](#T4){ref-type="table"}), as reported previously \[[@B18]\]. These findings suggest that the atherogenic effect of hypertriglyceridemia partially results from an increased sdLDL. However, more studies are needed to elucidate the primary mechanism that leads to the atherogenic effect mediated by TG.

To our surprise, the correlation of TG with sdLDL-C previously was weakened in the MetS group compared with the healthy group, and the contribution of TG to the sdLDL-C previously was consistently diminished in the MetS group ([Table 4](#T4){ref-type="table"}). When each group was subdivided according to whether they had hypertriglyceridemia (TG\>1.7 mmol/L) or not, the regression coefficient of TG for sdLDL-C previously was weakened by the presence of hypertriglyceridemia in both the MetS and healthy groups ([Supplemental Data Table S1](#S1){ref-type="supplementary-material"}). This implies that a more complicated mechanism of lipid metabolism contributed to the sdLDL-C concentration in MetS or hypertriglyceridemia compared with the healthy group, particularly having a normal TG concentration.

WC is regarded as a key component of MetS, as central obesity could drive all the pathophysiologic conditions constituting the other criteria of this syndrome \[[@B29]\]. Obesity itself also results in an increase in the formation of sdLDL by inducing changes in lipoprotein metabolism \[[@B30][@B31]\]. In the present study, healthy individuals who had an abnormal WC showed an increased sdLDL-C concentration; this tendency was not observed in patients with MetS ([Table 2](#T2){ref-type="table"}). Multiple linear regression analysis revealed this relationship as concordantly significant in both groups ([Table 4](#T4){ref-type="table"}), but relatively small contributions of WC to sdLDL-C concentration were noted (regression coefficients: 0.0055±0.0018 and 0.0045±0.0019, in the healthy and MetS group, respectively). While obesity is the major driving force of the other components of MetS, insulin resistance and compensatory hyperinsulinemia could predispose individuals to conditions related to CVD \[[@B32]\], and the insulin resistance correlates well with sdLDL-C concentration \[[@B33]\]. In the present study using HOMA-IR as an indicator of insulin resistance, weak correlation between insulin resistance and both sdLDL-C concentration and sdLDL-C/LDL-C ratio was observed (r=0.366 and 0.315, respectively). And the strength of correlation was weakened in the MetS group compared with the healthy population ([Supplemental Data Figure S1](#S2){ref-type="supplementary-material"}).

Low HDL-C concentration, in conjunction with hypertriglyceridemia and presence of sdLDL, constitutes the so-called atherogenic lipoprotein phenotype \[[@B34]\]. However, in the present study, while HDL-C concentration significantly contributed to LDL-C concentration and sdLDL-C/LDL-C ratio in the healthy population, it did not do so in patients with MetS ([Table 4](#T4){ref-type="table"}), opposite to the reported correlation between sdLDL particle number and HDL-C concentration in MetS \[15\]. As there seem to be different contributions of HDL subfractions to sdLDL-C, HDL2-C being more closely correlated with sdLDL-C than total HDL-C or HDL3-C \[[@B35]\], further studies utilizing HDL-C subfractions are needed to elucidate their association with sdLDL-C level or sdLDL-C/LDL-C ratio in patients with MetS.

In the Framingham Heart Study, hypertension and sdLDL particle number were significantly correlated in the MetS group \[[@B15]\]. In line with this report, both the sdLDL-C concentration and sdLDL-C/LDL-C ratio were significantly associated with DBP in the MetS group ([Table 4](#T4){ref-type="table"}). However, these associations were not observed in the healthy population. A study comparing LDL subfraction patterns of normotensive and hypertensive individuals without MetS also concluded that hypertension per se did not increase the proportion of sdLDL particles in this population \[[@B36]\]. Taken together, hypertension is the only factor among components of MetS that is more closely associated to sdLDL-C concentration in MetS than in healthy population. Thus there might be a different contribution of hypertension to the formation of sdLDL in MetS.

When the total number of MetS components was regarded as a simple tentative surrogate marker for the severity of MetS, it was found to be well associated with the number of sdLDL particles \[[@B15]\]. In our study, the sdLDL-C concentration and sdLDL-C/LDL-C ratio were concordantly elevated with the increasing number of MetS components, although the sdLDL-C concentration was not significantly different between MetS patients who had four and five MetS components ([Supplemental Data Figure S2](#S3){ref-type="supplementary-material"}).

This study has several limitations. As the study population was selected from a cohort to give nearly equal numbers in the subgroups, the natural distribution of metabolic parameters in the general population was abolished. Furthermore, because of differences in measurement methods and the ethnicity of the study population, our results are not directly comparable with those of previous studies \[[@B37]\].

In conclusion, among five MetS components, abnormal TG concentration was the only factor associated with sdLDL-C concentration and sdLDL-C/LDL-C ratio in both genders with or without MetS. In addition, TG concentration showed the strongest correlation with sdLDL-C concentration and sdLDL-C/LDL-C ratio among the five MetS components. Therefore, hypertriglyceridemia is a major factor associated with elevated concentrations of sdLDL-C in patients with MetS. Our results support the hypothesis that the atherogenic effect of hypertriglyceridemia is mediated by increased sdLDL-C; further studies are required to elucidate the underlying mechanism.
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###### Associations of sdLDL-C with metabolic variables in the presence of either metabolic syndrome or hypertriglyceridemia (TG \>1.7 mmol/L) determined by multiple linear regression analysis

![](alm-35-586-s001)

  Parameter                  MetS (n = 447)   Healthy population (n = 360)                                                                                   
  -------------------------- ---------------- ------------------------------ ---------------- -------------- ---------------- -------------- --------------- --------------
  Age (yr)                   0.0025±0.0029    0.3903                         0.0031±0.0018    0.0781         0.0020±0.0012    0.0827         0.0072±0.0038   0.0629
  WC (cm)                    0.0024±0.0034    0.4911                         0.0051±0.0022    0.0212         0.0043±0.0016    0.0083^\*^     0.0098±0.0051   0.0574
  SBP (mm Hg)                -0.0002±0.0023   0.9372                         -0.0025±0.0015   0.0997         0.0000±0.0015    0.9871         0.0018±0.0042   0.6715
  DBP (mm Hg)                -0.0015±0.0033   0.6594                         0.0060±0.0020    0.0031^\*^     -0.0011±0.0017   0.5153         0.0040±0.0049   0.4190
  Fasting glucose (mmol/L)   0.0283±0.0113    0.0147^\*^                     0.0216±0.0078    0.0061^\*^     0.0656±0.0259    0.0119^\*^     0.1134±0.0756   0.1373
  TG (mmol/L)                0.2148±0.0822    0.0109^\*^                     0.1526±0.0121    \<0.0001^\*^   0.2665±0.0368    \<0.0001^\*^   0.2128±0.0382   \<0.0001^\*^
  HDL-C (mmol/L)             0.1233±0.0966    0.2060                         -0.0261±0.0731   0.7208         0.0878±0.0370    0.0183^\*^     0.2492±0.1488   0.0977
  LDL-C (mmol/L)             0.2792±0.0300    \<0.0001^\*^                   0.3860±0.0191    \<0.0001^\*^   0.2490±0.0152    \<0.0001^\*^   0.2511±0.0422   \<0.0001^\*^

The components of MetS (WC, TG, HDL-C, SBP, DBP, FG), age, and LDL-C were included in the multiple linear regression analysis with an \"enter\" procedure, and *P* values \<0.05 are indicated by ^\*^.

Abbreviations: MetS, metabolic syndrome; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol.

###### Supplemental Data Fig. S1

Scatterplots showing the correlation between the plasma concentration of small dense LDL cholesterol (sdLDL-C) (A) or the sdLDL-C/LDL-C ratio (B) and the homeostasis model assessment of insulin resistance (HOMA-IR) in patients with MetS (●) and healthy population (◦). Linear regression curve for the two variables are indicated in solid line (for patients with MetS) or dashed line (for healthy population).

###### Supplemental Data Fig. S2

Progressive increase in the small dense LDL cholesterol (sdLDL-C) concentration in men (A) and women (B), and the sdLDL-C/LDL-C ratio in men (C) and women (D), as a function of the number of metabolic syndrome components (*P* for trend \< 0.001, for all).

![Scattergrams of the small dense LDL cholesterol (sdLDL-C) concentrations in a healthy population versus male (A) and female (B) patients with metabolic syndrome. The lines depict the median values and and interquartile ranges of each group, which were significantly different (*P*\<0.001) in both genders.](alm-35-586-g001){#F1}

###### Baseline characteristics of the study population

![](alm-35-586-i001)

  Characteristic                          Men (n = 406)         Women (n = 401)                                                                   
  --------------------------------------- --------------------- --------------------- --------------- --------------------- --------------------- ---------------
  Number                                  181                   225                   \-              179                   222                   \-
  Age (yr)                                46 (40-54)            51 (43-57)            \< 0.001        45 (38-53)            56 (50-62)            \< 0.001
  BMI (kg/m^2^)                           24.10 (22.38-25.68)   26.56 (25.20-28.15)   \< 0.001        21.91 (20.80-23.79)   25.55 (24.25-27.48)   \< 0.001
  WC (cm)                                 84 (79-88)            92 (90-96)            \< 0.001        73 (69-77)            84 (81-88)            \< 0.001
  SBP (mm Hg)                             116 (111-122)         128 (119-135)         \< 0.001        109 (104-116)         125 (116-137)         \< 0.001
  DBP (mm Hg)                             77 (69-81)            88 (82-93)            \< 0.001        70 (65-78)            82 (75-87)            \< 0.001
  Fasting glucose (mmol/L)                4.83 (4.55-5.05)      5.61 (5.00-6.49)      \< 0.001        4.66 (4.38-4.88)      5.27 (4.83-6.44)      \< 0.001
  Fasting insulin (mIU/L)                 4.1 (2.8-5.6)         6.5 (4.8-8.7)         \< 0.001        3.8 (2.5-4.8)         5.3 (3.9-7.1)         \< 0.001
  HOMA-IR                                 0.894 (0.655-1.302)   1.687 (1.184-2.369)   \< 0.001        0.818 (0.524-1.039)   1.302 (0.984-1.888)   \< 0.001
  TC (mmol/L)                             4.82 (4.33-5.34)      4.95 (4.33-5.59)      0.123           4.74 (4.25-5.46)      5.21 (4.61-5.78)      \< 0.001
  TG (mmol/L)                             1.42 (1.01-2.02)      2.43 (1.88-3.21)      \< 0.001        0.95 (0.80-1.41)      2.00 (1.73-2.52)      \< 0.001
  HDL-C (mmol/L)                          1.27 (1.11-1.48)      1.01 (0.93-1.17)      \< 0.001        1.53 (1.32-1.79)      1.17 (1.06-1.35)      \< 0.001
  LDL-C (mmol/L)                          3.08 (2.69-3.50)      3.08 (2.59-3.52)      0.840           2.93 (2.43-3.55)      3.32 (2.82-3.89)      \< 0.001
  Non-HDL-C (mmol/L)                      3.52 (2.98-3.96)      3.86 (3.26-4.53)      \< 0.001        3.19 (2.69-3.91)      3.94 (3.39-4.61)      \< 0.001
  sdLDL-C (mmol/L)                        0.88 (0.62-1.20)      1.16 (0.91-1.60)      \< 0.001        0.64 (0.47-0.89)      1.10 (0.85-1.39)      \< 0.001
  sdLDL-C (mmol/L), 2.5-97.5 percentile   0.30-1.86             0.49-2.31             \-              0.27-1.61             0.39-2.22             \-
  sdLDL-C/LDL-C (%)                       28.08 (21.74-37.00)   39.29 (32.21-48.50)   \< 0.001        21.37 (18.21-26.06)   33.20 (26.93-40.07)   \< 0.001
  LDL-C \< 2.6 mmol/L                     20.40%                24.40%                0.3383^\*^      30.20%                17.10%                0.0020^\*^
  LDL-C \> 4.14 mmol/L                    4.40%                 11.60%                0.0099^\*^      11.20%                17.60%                0.0723^\*^
  sdLDL-C \< 0.5 mmol/L                   13.80%                2.70%                 \< 0.0001^\*^   31.80%                6.30%                 \< 0.0001^\*^
  sdLDL-C \> 1.0 mmol/L                   38.10%                60.90%                \< 0.0001^\*^   15.10%                56.80%                \< 0.0001^\*^

Values are presented as the median (interquartile range), with the exception of the frequency data.

^\*^The chi-square test was employed to compare frequency data. Other characteristics were analyzed using the Mann-Whitney\'s U test.

Abbreviations: MetS, metabolic syndrome; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model of insulin resistance; TC, total cholesterol; TG, triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; sdLDL-C, small dense LDL cholesterol.

###### Differences in the medians of the sdLDL-C concentration and sdLDL-C/LDL-C ratio between subgroups divided according to whether subjects met or did not meet the criteria for each metabolic syndrome component

![](alm-35-586-i002)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group                Men (n=406)             Women (n=401)                                                                                                                                            
  -------------------- ----------------------- ----------------------- -------------------------- -------------------------- ----------------------- ----------------------- -------------------------- --------------------------
  Metabolic syndrome   1.16 (0.91-1.60)        39.29 (32.21-48.50)     1.10 (0.85-1.39)           33.20 (26.93-40.07)                                                                                   

  225                  225                     222                     222                                                                                                                              

   WC                  1.18 (0.92-1.59)\       1.13 (0.91-1.63)\       41.75 (35.87-51.98)\       38.39 (31.02-47.36)\       1.17 (0.88-1.37)\       1.09 (0.85-1.39)\       34.09 (29.39-40.56)\       33.12 (26.45-40.07)\
                       54                      171                     54                         171                        32                      190                     32                         190

   TG                  0.75 (0.59-0.95)^\*^\   1.26 (0.99-1.68)^\*^\   25.95 (22.44-31.45)^\*^\   41.75 (35.3-51.02)^\*^\    0.86 (0.68-1.06)^\*^\   1.18 (0.91-1.50)^\*^\   25.67 (22.00-31.22)^\*^\   35.75 (29.82-42.33)^\*^\
                       32                      193                     32                         193                        47                      175                     47                         175

   HDL-C               1.18 (0.92-1.68)\       1.16 (0.91-1.52)\       38.39 (30.48-47.57)\       40.24 (32.88-50.2)\        1.15 (0.82-1.51)\       1.08 (0.85-1.37)\       33.54 (25.80-40.64)\       33.12 (28.26-39.92)\
                       105                     120                     105                        120                        66                      156                     66                         156

   BP                  1.27 (0.91-1.65)\       1.14 (0.91-1.59)\       42.23 (33.76-49.22)\       38.53 (31.95-48.29)\       1.09 (0.89-1.46)\       1.10 (0.82-1.36)\       34.83 (28.68-41.90)\       32.58 (25.58-39.92)\
                       39                      186                     39                         186                        63                      159                     63                         159

   FG                  1.19 (0.96-1.59)\       1.09 (0.78-1.61)\       39.45 (32.81-48.29)\       39.10 (28.57-49.04)\       1.10 (0.85-1.38)\       1.08 (0.82-1.51)\       32.79 (26.85-39.17)\       33.91 (26.93-42.84)\
                       143                     82                      143                        82                         135                     87                      135                        87

  Healthy population   0.88 (0.62-1.20)        28.08 (21.74-37)        0.64 (0.47-0.89)           21.37 (18.21-26.06)                                                                                   

  181                  181                     179                     179                                                                                                                              

   WC                  0.87 (0.61-1.19)^\*^\   1.08 (0.74-1.39)^\*^\   27.89 (21.44-36.9)\        31.65 (26.62-43.73)\       0.61 (0.47-0.85)^\*^\   0.78 (0.60-1.08)^\*^\   21.08 (18.12-26.06)\       22.83 (19.70-25.98)\
                       158                     23                      158                        23                         146                     33                      146                        33

   TG                  0.72 (0.57-0.94)^\*^\   1.23 (0.98-1.53)^\*^\   23.28 (19.94-28.93)\*\     40.95 (32.04-51.09)^\*^\   0.60 (0.46-0.79)^\*^\   1.11 (0.92-1.53)^\*^\   20.58 (17.58-23.59)^\*^\   33.90 (28.33-37.48)^\*^\
                       115                     66                      115                        66                         152                     27                      152                        27

   HDL-C               0.85 (0.61-1.18)\       1.07 (0.87-1.28)\       27.46 (21.46-35.58)\*\     36.04 (31.18-47.88)^\*^\   0.62 (0.47-0.86)\       0.71 (0.53-0.99)\       21.07 (17.74-25.74)\       22.54 (20.07-30.32)\
                       156                     25                      156                        25                         145                     34                      145                        34

   BP                  0.88 (0.61-1.19)\       0.91 (0.69-1.37)\       28.08 (21.56-37.00)\       29.38 (21.74-37.32)\       0.65 (0.48-0.90)\       0.59 (0.40-0.84)\       21.49 (18.51-26.10)\       19.70 (16.67-23.55)\
                       155                     26                      155                        26                         164                     15                      164                        15

   FG                  0.88 (0.62-1.20)\       0.94 (0.29-1.26)\       28.18 (21.74-37.00)\       24.93 (13.29-39.35)\       0.64 (0.47-0.89)\       \-                      21.37 (18.21-26.06)\       \-
                       178                     3                       178                        3                          179                                             179                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BP component was considered positive when subjects met metabolic syndrome criteria for systolic blood pressure or diastolic blood pressure. Values are presented as the median (interquartile range).

sdLDL-C concentration (mmol/L) or sdLDL-C/LDL-C ratio (%) of those who have the component and not in each gender group were compared using the Mann-Whitney\'s U test, and *P*\<0.05 are indicated by ^\*^.

Abbreviations: BP, blood pressure; FG, fasting glucose; see [Table 1](#T1){ref-type="table"}.

###### Associations of the sdLDL-C concentration and sdLDL-C/LDL-C ratio with metabolic variables in each gender determined by multiple linear regression analysis

![](alm-35-586-i003)

  Parameter                  Men (n = 406)    Women (n=401)                                                                                    
  -------------------------- ---------------- --------------- ---------------- -------------- ---------------- -------------- ---------------- --------------
  Age (yr)                   0.0006±0.0016    0.7126          0.0363±0.0456    0.4259         0.0042±0.0012    0.0007^\*^     0.1638±0.0379    \<0.0001^\*^
  WC (cm)                    0.0078±0.0022    0.0005^\*^      0.2501±0.0644    0.0001^\*^     0.0004±0.0018    0.8129         0.0269±0.0535    0.6150
  SBP (mm Hg)                -0.0029±0.0017   0.0873          -0.1066±0.0490   0.0303^\*^     -0.0001±0.0012   0.9223         -0.0007±0.0363   0.9836
  DBP (mm Hg)                0.0036±0.0020    0.0713          0.0969±0.0588    0.1000         0.0013±0.0016    0.4366         0.0502±0.0497    0.3131
  Fasting glucose (mmol/L)   0.0198±0.0099    0.0467^\*^      0.4983±0.2903    0.0868         0.0215±0.0068    0.0017^\*^     0.4732±0.2069    0.0227^\*^
  TG (mmol/L)                0.1776±0.0112    \<0.0001^\*^    7.4390±0.3270    \<0.0001^\*^   0.2420±0.0143    \<0.0001^\*^   7.3739±0.4339    \<0.0001^\*^
  HDL-C (mmol/L)             0.0430±0.0617    0.4864          3.3684±1.8020    0.0623         0.0441±0.0404    0.2767         -0.0022±1.2312   0.9986
  LDL-C (mmol/L)             0.3911±0.0204    \<0.0001^\*^    0.3981±0.5957    0.5043         0.3005±0.0137    \<0.0001^\*^   -0.1538±0.4164   0.7122

The components of metabolic syndrome (WC, TG, HDL-C, SBP, DBP, fasting glucose), age, and LDL-C were included in the multiple linear regression analysis with an \"enter\" procedure, and *P* values \<0.05 are indicated by ^\*^.

Abbreviations: See [Table 1](#T1){ref-type="table"}.

###### Associations of the sdLDL-C concentration and sdLDL-C/LDL-C ratio with metabolic variables in patients with metabolic syndrome and healthy controls

![](alm-35-586-i004)

  Parameter                  MetS (n=447)       Healthy population (n=360)                                                                                            
  -------------------------- ------------------ ---------------------------- ------------------ --------------- ------------------ --------------- ------------------ ---------------
  Age (yr)                   0.0025 ± 0.0016    0.1183                       0.0698 ± 0.0455    0.1257          0.0022 ± 0.0013    0.0764          0.0780 ± 0.0406    0.0557
  WC (cm)                    0.0045 ± 0.0019    0.0226^\*^                   0.1200 ± 0.0561    0.0329^\*^      0.0055 ± 0.0018    0.0020^\*^      0.2161 ± 0.0571    0.0002^\*^
  SBP (mm Hg)                -0.0024 ± 0.0013   0.0729                       -0.0653 ± 0.0388   0.0927          0.0003 ± 0.0016    0.8678          -0.0255 ± 0.0521   0.6241
  DBP (mm Hg)                0.0047 ± 0.0018    0.0102^\*^                   0.1303 ± 0.0521    0.0127^\*^      -0.0006 ± 0.0018   0.7561          0.0102 ± 0.0585    0.8612
  Fasting glucose (mmol/L)   0.0172 ± 0.0068    0.0121^\*^                   0.4015 ± 0.1966    0.0418^\*^      0.0990 ± 0.0277    0.0004^\*^      3.0126 ± 0.8919    0.0008^\*^
  TG (mmol/L)                0.1747 ± 0.0105    \< 0.0001^\*^                6.9518 ± 0.3011    \< 0.0001^\*^   0.2706 ± 0.0157    \< 0.0001^\*^   9.1815 ± 0.5049    \< 0.0001^\*^
  HDL-C (mmol/L)             0.0077 ± 0.0634    0.9030                       0.4235 ± 1.8250    0.8166          0.0935 ± 0.0425    0.0287^\*^      3.0332 ± 1.3720    0.0277^\*^
  LDL-C (mmol/L)             0.3830 ± 0.0167    \< 0.0001^\*^                -0.0060 ± 0.4802   0.9900          0.2510 ± 0.0160    \< 0.0001^\*^   -0.6816 ± 0.5151   0.1866

The components of metabolic syndrome (WC, TG, HDL-C, SBP, DBP, fasting glucose), age, and LDL-C were included in the multiple linear regression analysis with an \"enter\" procedure, and *P* values \<0.05 are indicated by ^\*^.

Abbreviations: See [Table 1](#T1){ref-type="table"}.

[^1]: ^\*^Yonggeun Cho and Sang-Guk Lee contributed equally to this work.
